TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05672524: A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Sponsor: Memorial Sloan Kettering Cancer Center · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 37 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,524,600

Rescue Site Savings

+$1,016,400

Unlock Full NCT05672524 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05672524 Rescue Dossier →